Global Gastrointestinal Cancer Drugs Market growing at a CAGR of 7.0% from 2023 to 2031
Category : Healthcare | Published Date : Nov 2023 | Type : Press Release
Key Market Overview
Consegic Business Intelligence analyzes that the gastrointestinal cancer drug market is predicted to grow at a compound annual growth rate of 7.0% from 2023 to 2031 and is expected to reach USD 6,916.52 million in 2031 and 4,013.39 million in 2023 which was valued at USD 3,750.00 million in 2022.
The report highlights the growing incidences of gastrointestinal cancer across the globe and advancements in the research and development activities in gastrointestinal cancer, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the Gastrointestinal Cancer Drugs market.
Global Gastrointestinal Cancer Drugs Market By Overview
The gastrointestinal cancer drug market is bifurcated into the drug type, route of administration and distribution channel. Based on drug type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others. In 2022, chemotherapy segment dominate the overall gastric cancer drug market. Based on the route of administration, the market is segmented into oral and injectable drugs. In 2022, injectable drugs segment dominate the overall ethylene oxide market. Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, retail pharmacies, online pharmacies, and others. In 2022, hospital pharmacies segment dominate the overall gastric cancer drug market.
Get Free SampleMarket Dynamics
Driver:
- Growing incidences of gastrointestinal cancer.
- Advancements in the research and development activities in gastrointestinal cancer.
Restraints:
- Expensive treatment and limitations associated with the drugs.
Market Segmentation:
| Report Attributes | Report Details |
| By Drug Type | Chemotherapy, Targeted therapy, Immunotherapy and Others |
| By Route of Administration | Oral and Injectable |
| By Distribution Channel | Hospital pharmacies, Specialty pharmacies, Retail pharmacies, Online pharmacies and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as AstraZeneca, Astellas Pharma Inc., Seagen Inc., and BeiGene which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the gastrointestinal cancer drug market is expected to witness substantial growth in the coming years due the increasing approval of new targeted drugs, therapies and biosimilars in key regions such as Asia Pacific, the North America and Europe.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- Merck & Co
- Astellas Pharma Inc
- Biocon
- AstraZeneca
- Novartis Pharmaceuticals Corporation
- F. Hoffmann-La Roche Ltd
- Mylan N.V.
- BeiGene, Inc.
- Bristol-Myers Squibb Company.
- Amgen Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Celltrion Healthcare Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Seagen Inc.
- West Pharmaceutical Services, Inc.
- Corning Incorporated
